- Home
- ADAP
as 09-12-2025 4:00pm EST
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
| Founded: | 2008 | Country: | United Kingdom |
| Employees: | N/A | City: | ABINGDON, OXFORDSHIRE |
| Market Cap: | 21.3M | IPO Year: | 2015 |
| Target Price: | $1.02 | AVG Volume (30 days): | 62.3M |
| Analyst Decision: | Hold | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.04 - $1.17 | Next Earning Date: | 11-12-2025 |
| Revenue: | $65,084,999 | Revenue Growth: | -53.99% |
| Revenue Growth (this year): | -77.09% | Revenue Growth (next year): | 52.35% |
Stock Insider Trading Activity of Adaptimmune Therapeutics plc (ADAP)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Wood Gavin | ADAP | Chief Financial Officer | Sep 2 '25 | Sell | $0.01 | 96,000 | $950.40 | 0 | |
| Behbahani Ali | ADAP | N/A | Aug 18 '25 | Sell | $0.01 | 14,671,794 | $176,061.53 | 0 | |
| Behbahani Ali | ADAP | N/A | Aug 15 '25 | Sell | $0.01 | 4,828,206 | $53,110.27 | 0 |
Latest Adaptimmune Therapeutics plc News
ADAP Breaking Stock News: Dive into ADAP Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
MT Newswires
8 days ago
European Equities Traded in the US as ADRs Are Little Changed in Friday Trading
MT Newswires
9 days ago
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
MT Newswires
3 months ago
Mizuho Downgrades Adaptimmune Therapeutics to Neutral From Outperform, Cuts Price Target to $0.50 From $1.50 on Solvency Concerns
MT Newswires
3 months ago
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading
MT Newswires
3 months ago
European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading
MT Newswires
3 months ago
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
GuruFocus.com
4 months ago
Adaptimmune Therapeutics PLC (ADAP) Q1 2025 Earnings Call Highlights: Strong Tecelra Launch ...
Compare ADAP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADAP Adaptimmune Therapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.